The Manufacturers Life Insurance Company Sells 744 Shares of Catalent, Inc. (NYSE:CTLT)

The Manufacturers Life Insurance Company lowered its stake in Catalent, Inc. (NYSE:CTLT) by 0.1% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 657,289 shares of the company’s stock after selling 744 shares during the period. The Manufacturers Life Insurance Company owned approximately 0.36% of Catalent worth $39,812,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also bought and sold shares of CTLT. Bank of Montreal Can grew its stake in Catalent by 181.5% during the third quarter. Bank of Montreal Can now owns 1,813,167 shares of the company’s stock worth $109,388,000 after buying an additional 1,169,044 shares in the last quarter. Dynamic Technology Lab Private Ltd acquired a new stake in shares of Catalent during the 3rd quarter worth approximately $1,131,000. Citigroup Inc. increased its stake in Catalent by 26.2% in the third quarter. Citigroup Inc. now owns 204,923 shares of the company’s stock valued at $12,412,000 after acquiring an additional 42,517 shares during the last quarter. Charles Schwab Investment Management Inc. raised its position in Catalent by 1.1% during the third quarter. Charles Schwab Investment Management Inc. now owns 1,656,506 shares of the company’s stock valued at $100,335,000 after purchasing an additional 17,681 shares in the last quarter. Finally, Alpine Associates Management Inc. lifted its stake in Catalent by 3.4% during the third quarter. Alpine Associates Management Inc. now owns 2,131,126 shares of the company’s stock worth $129,082,000 after purchasing an additional 69,875 shares during the last quarter.

Insider Buying and Selling

In other Catalent news, Director Michelle R. Ryan sold 2,800 shares of Catalent stock in a transaction that occurred on Monday, November 11th. The stock was sold at an average price of $59.70, for a total value of $167,160.00. Following the completion of the sale, the director now directly owns 10,835 shares in the company, valued at approximately $646,849.50. The trade was a 20.54 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider David Mcerlane sold 1,994 shares of the stock in a transaction that occurred on Thursday, September 26th. The stock was sold at an average price of $59.97, for a total value of $119,580.18. Following the transaction, the insider now owns 36,304 shares in the company, valued at $2,177,150.88. The trade was a 5.21 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 5,114 shares of company stock valued at $305,931 over the last quarter. Insiders own 0.31% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on CTLT. Robert W. Baird reiterated a “neutral” rating and issued a $63.50 price target on shares of Catalent in a research note on Tuesday, September 24th. StockNews.com downgraded Catalent from a “hold” rating to a “sell” rating in a research note on Friday, November 22nd. William Blair reissued a “market perform” rating on shares of Catalent in a report on Tuesday, September 3rd. Finally, Baird R W lowered shares of Catalent from a “strong-buy” rating to a “hold” rating in a report on Tuesday, September 24th. One research analyst has rated the stock with a sell rating and seven have given a hold rating to the company. Based on data from MarketBeat, Catalent presently has a consensus rating of “Hold” and an average target price of $63.40.

Catalent Trading Up 0.4 %

Shares of NYSE CTLT opened at $61.00 on Friday. The company has a debt-to-equity ratio of 1.38, a quick ratio of 1.96 and a current ratio of 2.51. Catalent, Inc. has a 52-week low of $36.74 and a 52-week high of $61.50. The stock has a market cap of $11.07 billion, a P/E ratio of -26.99, a price-to-earnings-growth ratio of 2.44 and a beta of 1.16. The firm has a 50 day moving average price of $59.86 and a two-hundred day moving average price of $58.41.

Catalent (NYSE:CTLT) last posted its quarterly earnings data on Tuesday, November 5th. The company reported ($0.13) EPS for the quarter, missing analysts’ consensus estimates of $0.05 by ($0.18). The company had revenue of $1.02 billion during the quarter, compared to analyst estimates of $1.06 billion. Catalent had a negative return on equity of 0.66% and a negative net margin of 9.28%. Catalent’s revenue was up 4.2% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.10) earnings per share. As a group, equities analysts forecast that Catalent, Inc. will post 0.84 EPS for the current year.

About Catalent

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.